Evidence map›Paper›PMID 25860122›Full record

ArticleMolecular imaging and biology2015

Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model.

Daniela Baldoni, Robert Waibel, Peter Bläuenstein, Filippo Galli, Violetta Iodice, Alberto Signore, Roger Schibli, Andrej Trampuz

Open access · hybridAbstract read
In one paragraph

Article in Molecular imaging and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  3. Radiometal chelators for infection diagnostics.Frontiers in nuclear medicine · 2023
    Article
  4. Pathophysiology and Molecular Imaging of Diabetic Foot Infections.International journal of molecular sciences · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. ACS omega · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Daniela BaldoniInfectious Diseases Research Laboratory, Department of Biomedicine, University Hospital, Basel, Switzerland.
Robert WaibelCenter for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen PSI, Switzerland.
Peter BläuensteinCenter for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen PSI, Switzerland.
Filippo GalliNuclear Medicine, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Ospedale S. Andrea, via di Grottarossa 1035, 00189, Rome, Italy.
Violetta IodiceNuclear Medicine, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Ospedale S. Andrea, via di Grottarossa 1035, 00189, Rome, Italy.
Alberto SignoreNuclear Medicine, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Ospedale S. Andrea, via di Grottarossa 1035, 00189, Rome, Italy. alberto.signore@uniroma1.it.
Roger SchibliCenter for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen PSI, Switzerland.
Andrej TrampuzSeptic Surgery Unit, Center for Musculoskeletal Surgery, Charité - University of Medicine, Berlin, Germany.
Paul Scherrer Institute · CHAzienda Ospedaliera Sant'Andrea · ITCharité - Universitätsmedizin Berlin · DEUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVitamin B12 (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were followed by biodistribution studies in a mouse model of foreign body infection. PROCEDURES: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. [(57)Co]Cbl, [(67)Ga]citrate and [(99m)Tc]DTPA served as reference compounds. The in vitro competitive binding of [(57)Co]Cbl or [(99m)Tc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37 and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [(57)Co]Cbl and [(99m)Tc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice.

resultsMaximum binding (mean ± SD) of [(57)Co]Cbl to viable E. coli was 81.7 ± 2.6 % and to S. aureus 34.0 ± 6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of [(99m)Tc]PAMA(4)-Cbl was 100-fold and 3-fold lower than the one of [(57)Co]Cbl for E. coli and S. aureus, respectively. In vivo, [(99m)Tc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at 30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of [(99m)Tc]DTPA, which showed similar biodistribution in infected and sterile mice. [(57)Co]Cbl gradually accumulated in cages with peaks % ID between 3.58 and 4.83 % achieved from 24 to 48 h. Discrimination for infection occurred only in E. coli-infected mice, at 72 h p.i. [(67)Ga]citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to 72 h p.i. (P < 0.05).

conclusionCbl displayed rapid and specific in vitro binding to test strains. [(99m)Tc]PAMA(4)-Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being a promising candidate for imaging infections in humans.

Indexed as

Drug Delivery SystemsAnimalsColony Count, MicrobialEscherichia coliForeign-Body ReactionIn Vitro TechniquesMiceMice, Inbred C57BLStaphylococcus aureusTechnetiumVitamin B 12TechnetiumVitamin B 1299mTcEscherichia coliInfection imagingStaphylococcus aureusVitamin B12

Identifiers

PMID25860122
PMCPMC4641156
OpenAlexW2005524757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.